Posted on

Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study

Share

At this year’s European Society of Cardiology (ESC) Congress, positive results were presented from Bayer’s FIGARO-DKD Phase III trial of Kerendia (finerenone), providing insight into the drug’s ability to reduce risk of morbidity and mortality in diabetic kidney disease patients. The positive data from the FIGARO-DKD study will help support the use of finerenone to improve cardiorenal outcomes for kidney disease and type 2 diabetes (T2D) patients, according to GlobalData, a leading data and analytics company.
The FIGARO-DKD study, showed that cardiovascular benefit was mainly driven by a 29% decrease in hospitalization for heart failure. Bayer previously completed …

Read More